ePoster 

Die hochgeladenen ePoster sind nur für eingeloggte Teilnehmer ersichtlich. 

Bitte loggen Sie sich ein, um zu den ePoster zu gelangen. 

Hier geht es zum Log- in

 

Detaillierte Beitrags-Information

Zurück zur Liste

Beitragstitel Retrospective Analysis of 12 months Glaucoma Implant Efficacy: XEN45 versus PreserFlo
Beitragscode P10
Autor:innen
  1. Giulia Ariana Saletta 1. Augenklinik, Universitätsspital Basel, 2. Institut für medizinische Genetik und Pathologie, Universitätsspital Basel Präsentierende:r
  2. Antonios Alexoudis AUGENKLINIK WETTINGEN
  3. Zisis Gkatzioufas Universitätsspital Basel
  4. Matthias Grieshaber Augenklinik, Universitätsspital Basel
  5. Anthia Papazoglou KSA Aarau
  6. Markus Tschopp Kantonsspital Aarau
  7. Marc Töteberg-Harms Augenklinik Universitätsspital Zürich
  8. Konstantin Gugleta Universitätsspital Basel
Präsentationsform ePoster
Themengebiete
  • Glaucoma
Abstract-Text Purpose: Glaucoma surgery has seen a number of new implant devices lately, using various techniques for intraocular pressure (IOP) reduction. Two implants introduced during the past couple of years, XEN and PreserFlo, are both designed for controlled subconjunctival filtration. There are two independent ongoing Swiss multicenter studies which are set to retrospectively analyse the efficacy and safety of these two devices. In this particular study we analysed the data subset from Basel and report preliminary results of the retrospective comparison between these two methods.

Subjects and Methods: XEN45 implantation technique was introduced in Basel University Hospital in 2016, and PreserFlo in 2018. Operated patients were clinically followed up and their data retrospectively analysed from medical records. Only stand-alone procedures, without combined phacoemulsification, were considered in this analysis; the lens status however was neither an inclusion nor exclusion criterion. Further inclusion criteria were the diagnosis of open-angle glaucoma, no previous glaucoma surgery other than laser trabeculoplasty, and complete medical records during the 12 months follow-up. Data of first consecutive thirty operated patients with each technique, fulfilling the criteria, were included in the analysis. Primary outcome measure was the IOP reduction during a 12 month postoperative period, as well as the number of IOP-reducing drugs. The number of subsequent surgical interventions and complications / adverse events are descriptively reported.

Results: Patient age, gender, ophthalmological diagnosis and initial preoperative IOP were well balanced between the two groups. Postoperative IOP course was comparable between the two methods for the first 12 months. IOP measurements were taken preoperatively and then at first postop. day / week 1 / month 1 / months 3/6/12 respectively for PreserFlo vs. XEN45 (mmHg): 23.6 vs. 24.9; 9.0 vs.8.9; 11.4 vs. 10.6; 13.0 vs.18.3; 16.8 vs.15.1; 15.9 vs.15.0; 15,4 vs.14.5. IOP-reducing medications were also comparable between the two groups. Subsequent interventions were more frequent in the XEN (13) than in the PreserFlo group (7).

Conclusion: Both analysed methods demonstrate satisfactory intraocular pressure control within a 12 month postoperative period with practically no serious adverse events / complications, but with relatively high number of subsequent interventions, particularly in the XEN group.